Abstract
Olprinone, a phosphodiesterase (PDE) 3 inhibitor, is used to treat heart failure due to its positive inotropic and vasodilative effects. Selective inhibition of the PDE 3 isozyme increases intracellular adenosine 35-cyclic monophosphate and enhances Ca2+ influx into cardiac muscle cells. The most significant advantage of PDE 3 inhibitors is their ability not only to enhance myocardial contraction, but to reduce, through vasodilatory action, the stress to which the heart is subjected. In peripheral vessels, the decrease of cytosolic free Ca2+ induces the vasorelaxation of vascular smooth muscle cells. In this way, olprinone reduces mean aortic and pulmonary artery pressures. Additionally, olprinone exerts differential vasodilatory effects on peripheral vessels in each organ, based on the differences in the distribution of PDE 3 among the organs. With respect to the cerebral circulation, olprinone augments blood flow in the cerebral cortex through direct vasodilatory effects on small cerebral arter ies or arterioles. Olprinone increases hepatosplanchnic blood flow and improves oxygen supply. While long-term therapy with PDE 3 inhibitors in patients with chronic heart failure may accelerate the progress of the underlying disease and provoke serious ventricular arrhythmia, olprinone shows good potential for short-term treatment in patients who have experienced severe heart failure or patients who have undergone cardiac surgery.
Keywords: Phosphodiesterase 3 inhibitor, olprinone, cardiac function, cerebral circulation, arterial distensibility, renal function, splanchnic circulation, bronchodilator
Current Vascular Pharmacology
Title: The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Volume: 4 Issue: 1
Author(s): Takashi Ueda and Katsufumi Mizushige
Affiliation:
Keywords: Phosphodiesterase 3 inhibitor, olprinone, cardiac function, cerebral circulation, arterial distensibility, renal function, splanchnic circulation, bronchodilator
Abstract: Olprinone, a phosphodiesterase (PDE) 3 inhibitor, is used to treat heart failure due to its positive inotropic and vasodilative effects. Selective inhibition of the PDE 3 isozyme increases intracellular adenosine 35-cyclic monophosphate and enhances Ca2+ influx into cardiac muscle cells. The most significant advantage of PDE 3 inhibitors is their ability not only to enhance myocardial contraction, but to reduce, through vasodilatory action, the stress to which the heart is subjected. In peripheral vessels, the decrease of cytosolic free Ca2+ induces the vasorelaxation of vascular smooth muscle cells. In this way, olprinone reduces mean aortic and pulmonary artery pressures. Additionally, olprinone exerts differential vasodilatory effects on peripheral vessels in each organ, based on the differences in the distribution of PDE 3 among the organs. With respect to the cerebral circulation, olprinone augments blood flow in the cerebral cortex through direct vasodilatory effects on small cerebral arter ies or arterioles. Olprinone increases hepatosplanchnic blood flow and improves oxygen supply. While long-term therapy with PDE 3 inhibitors in patients with chronic heart failure may accelerate the progress of the underlying disease and provoke serious ventricular arrhythmia, olprinone shows good potential for short-term treatment in patients who have experienced severe heart failure or patients who have undergone cardiac surgery.
Export Options
About this article
Cite this article as:
Ueda Takashi and Mizushige Katsufumi, The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203072
DOI https://dx.doi.org/10.2174/157016106775203072 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Hematocrit-lowering Effect Following Inactivation of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Current Topics in Medicinal Chemistry The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Recent Advances and Patents on Novel Devices for Minimally Invasive Treatment of Functional Mitral Regurgitation
Recent Patents on Biomedical Engineering (Discontinued) Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry microRNA Decay: Refining microRNA Regulatory Activity
MicroRNA Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry Shock – Classification and Pathophysiological Principles of Therapeutics
Current Cardiology Reviews NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry 4,7-Dihydroindole: A Synthon for the Preparations of 2-Substituted Indoles
Current Organic Synthesis Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy